Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales

Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales
nhigginsdunn
Thu, 06/03/2021 – 07:31